Claims
- 1. A compound of the formula: ##STR8## wherein R.sup.1 is alkyl having from 8 to 24 carbon atoms;
- R.sup.2 is alkyl having from 1 to 6 carbon atoms or unsubstituted or substituted phenyl of the formula: ##STR9## wherein Y is a hydrogen atom, halo having an atomic weight of from about 19 to 80, alkyl of from 1 to 4 carbon atoms, or alkoxy of from 1 to 4 carbon atoms;
- R.sup.3 is a hydrogen atom, halo having an atomic weight of from about 19 to 80, alkyl having from 1 to 3 carbon atoms or alkoxy having from 1 to 3 carbon atoms;
- R.sup.4 is a hydrogen atom, or alkyl having from 1 to 6 carbon atoms;
- n is 0 or 1; and
- Z.sup..crclbar. is an anion forming a pharmaceutically acceptable non-toxic salt of the corresponding cation;
- provided that R.sup.4 is alkyl when R.sup.2 is other than alkyl.
- 2. A compound of claim 1 in which Z is tetrafluoroborate.
- 3. A compound of claim 1 in which R.sup.4 is alkyl.
- 4. A compound of claim 1 in which R.sup.2 is alkyl.
- 5. A compound of claim 1 in which n is 0.
- 6. A compound of claim 1 in which R.sup.2 is unsubstituted or substituted phenyl.
- 7. A compound of claim 1 in which n is 1.
- 8. The compound of claim 1 which is o-carbethoxyphenyl-n-propyl-n-octadecylsulfonium tetrafluoroborate.
- 9. The compound of claim 1 which is o-carbethoxyphenyl-n-propyl-n-octadecylsulfonium p-toluenesulfonate.
- 10. The compound of claim 1 which is p-(.alpha.-carbethoxy)-tolyl-n-tetradecyl-phenylsulfonium tetrafluoroborate.
- 11. A compound of inhibiting or retarding the passage of glucose into the blood in a mammal, comprising administering to a mammal an amount of a compound of claim 1, effective in inhibiting or retarding the passage of glucose into the blood of the mammal.
- 12. A method of claim 11 in which R.sup.1 is alkyl having from 10 to 20 carbon atoms.
- 13. A method of claim 11 in which the compound is administered in a solid form.
- 14. A method of claim 13 in which the compound is o-carbethoxyphenyl-n-propyl-n-octadecylsulfonium tetrafluoroborate.
- 15. A composition comprising in a unit dosage form a pharmaceutically acceptable carrier and from about 25 to 1000 milligrams of a compound as defined in claim 1.
- 16. A composition of claim 15 in which R.sup.1 of the compound is alkyl having from 10 to 20 carbon atoms.
- 17. A composition of claim 15 in which the carrier is solid.
- 18. A composition of claim 15 in which the compound is o-carbethoxyphenyl-n-propyl-n-octadecylsulfonium tetrafluoroborate.
- 19. A composition of claim 15 which is in the form of a tablet or hard-filled capsule.
- 20. The compound of claim 1 which is o-carbethoxyphenyl-isopropyl-n-octadecylsulfonium tetrafluoroborate.
- 21. A method of claim 11 in which the compound is administered at from about 60 to 3600 milligrams per day.
- 22. The method of claims 11 or 21 in which the compound is o-carbethoxyphenyl-n-propyl-octadecylsulfonium tetrafluoroborate.
- 23. A pharmaceutical composition comprising an amount of a compound of claim 1 effective in inhibiting or retarding the passage of glucose into the blood of said mammal and a non-toxic pharmaceutically-acceptable carrier.
- 24. A composition of claim 23 in which the compound is o-carbethoxyphenyl-n-propyl-octadecylsulfonium tetrafluoroborate.
- 25. A composition of claim 23 in which the compound is present in an amount of from about 15 to 1200 milligrams.
- 26. A method of claim 11 in which post-prandial hyperglycemia is treated in a diabetic subject.
- 27. A method of claim 11 in which obesity is treated.
Parent Case Info
This is a continuation-in-part of copending application Ser. No. 88,826 filed Oct. 26, 1979, abandoned, which in turn is a continuation-in-part of then copending application Ser. No. 929,424 filed July 31, 1978 (now abandoned).
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
3600437 |
Marshall |
Aug 1971 |
|
Non-Patent Literature Citations (1)
Entry |
Tsugio, et al. "Chemical Abstract" vol. 70, p. 28546b (1969). |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
88826 |
Oct 1979 |
|
Parent |
929424 |
Jul 1978 |
|